MIRA Pharmaceuticals, Inc. (MIRA) stock
Close on Nov 18, 2026Market cap $24.84MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $24.84M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.04
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$9.48M
- EPS, diluted
- -$1.39
- Book value per share
- $0.19
- Diluted shares
- 42M
Trading
- Previous close
- $0.64
- Open
- $0.65
- Day's range
- $0.58 – $0.65
- Volume
- 162,175
- Average volume (20 days)
- 158,924
- 52-week range
- $0.51 – $1.69
- RSI (14 days)
- 44.3
- Volatility (1 year)
- 72.8%
- Relative volume
- 0.35×
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.
| Period | MIRA | S&P 500 | Difference | MIRA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.5% | -4.3% | −2.2 pts | ||
| 3 months | -22.7% | -4.6% | −18.1 pts | ||
| Year to date | -60.9% | +7.9% | −68.8 pts | ||
| 1 year | -58.1% | +11.8% | −69.9 pts | ||
| 3 years | -82.2% | +68.0% | −150.2 pts | -43.7% | +18.9% |
| 5 years | +5810.0% | +66.2% | +5743.8 pts | +126.1% | +10.7% |
| 10 years | +5810.0% | +291.3% | +5518.7 pts | +50.4% | +14.6% |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Net income
EPS, diluted
Press releases
Releases MIRA Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About MIRA Pharmaceuticals
Pharmaceutical Preparations
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company focused on advancing novel oral therapeutics for neurologic, neuropsychiatric, metabolic, and addiction-related disorders. Its product candidate pipeline comprises Ketamir-2, an NMDA receptor modulator being evaluated for neuropathic and inflammatory pain indications such as chemotherapy-induced peripheral neuropathy; MIRA-55, an oral cannabinoid analog targeting inflammatory pain, anxiety, and cognitive impairment; and SKNY-1, an oral therapeutic candidate aimed at metabolic regulation and craving-related behaviors, including weight management and nicotine dependence. The company operates in the biotechnology and healthcare sector, developing therapies intended for patients suffering from acute and chronic medical conditions.
Company profile, executives and historyMIRA Pharmaceuticals stock: common questions
What is MIRA Pharmaceuticals's stock price?
MIRA closed at $0.59 on Nov 18, 2026, down 7.66% on the day. Over the past 52 weeks it traded between $0.51 and $1.69.
What is MIRA Pharmaceuticals's market cap?
MIRA Pharmaceuticals was worth $24.84M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.
What is MIRA's P/E ratio?
MIRA Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.39), so it has no meaningful P/E ratio.
Does MIRA Pharmaceuticals pay a dividend?
No. MIRA Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has MIRA stock performed over the past year?
Including dividends, MIRA returned -58.1% over the past year, against +11.8% for the S&P 500.
How many MIRA shares are sold short?
0M shares were sold short at the latest FINRA report, 0.74% of the float, or 1.4 days of average trading volume.
Who are MIRA Pharmaceuticals's competitors?
Companies most similar to MIRA Pharmaceuticals by business, industry and size include KTTA, MPLT, VTGN, OGEN, NRXP.
See a number that looks wrong?